Transgenic expression of a myostatin inhibitor derived from follistatin increases skeletal muscle mass and ameliorates dystrophic pathology in<i>mdx</i>mice
-
- Masashi Nakatani
- Division for Therapies Against Intractable DiseasesInstitute for Comprehensive Medical SciencesFujita Health UniversityToyoakeAichiJapan
-
- Yuka Takehara
- The Institute for Enzyme ResearchThe University of TokushimaTokushimaJapan
-
- Hiromu Sugino
- The Institute for Enzyme ResearchThe University of TokushimaTokushimaJapan
-
- Mitsuru Matsumoto
- The Institute for Enzyme ResearchThe University of TokushimaTokushimaJapan
-
- Osamu Hashimoto
- Laboratories of Experimental Animal ScienceKitasato University School of Veterinary Medicine and Animal SciencesTowadaAomoriJapan
-
- Yoshihisa Hasegawa
- Division for Therapies Against Intractable DiseasesInstitute for Comprehensive Medical SciencesFujita Health UniversityToyoakeAichiJapan
-
- Tatsuya Murakami
- Division for Therapies Against Intractable DiseasesInstitute for Comprehensive Medical SciencesFujita Health UniversityToyoakeAichiJapan
-
- Akiyoshi Uezumi
- Division for Therapies Against Intractable DiseasesInstitute for Comprehensive Medical SciencesFujita Health UniversityToyoakeAichiJapan
-
- Shin'ichi Takeda
- Department of Molecular TherapyNational Institute of NeuroscienceNational Center of Neurology and PsychiatryKodairaTokyoJapan
-
- Sumihare Noji
- Department of Biological Science and TechnologyFaculty of EngineeringThe University of TokushimaTokushimaJapan
-
- Yoshihide Sunada
- Division of NeurologyDepartment of Internal MedicineKawasaki Medical SchoolKurashikiOkayamaJapan
-
- Kunihiro Tsuchida
- Division for Therapies Against Intractable DiseasesInstitute for Comprehensive Medical SciencesFujita Health UniversityToyoakeAichiJapan
収録刊行物
-
- The FASEB Journal
-
The FASEB Journal 22 (2), 477-487, 2007-09-24
Wiley